Introduction
============

Intrahepatic cholangiocarcinoma is the second most common primary cancer of the liver, and arises from malignant transformation of epithelial tissue in the small bile ducts. The prognosis of intrahepatic cholangiocarcinoma is very poor, with median survival for patients who do not undergo surgery being 6 months, and the 5-year survival rate for patients following complete resection being only 20%--40%.[@b1-ott-5-255],[@b2-ott-5-255] Being of different embryological origin, intrahepatic cholangiocarcinoma differs from extrahepatic cholangiocarcinoma and metastatic adenocarcinoma of the liver in both morphology and molecular background.[@b3-ott-5-255] In recent decades, the incidence of and mortality from intrahepatic cholangiocarcinoma has progressively increased, whilst being stable or slightly decreased for extrahepatic cholangiocarcinoma.[@b4-ott-5-255] Different stem cell niches have been identified recently in the liver and biliary tree, which might partly account for the difference between intrahepatic and extrahepatic cholangiocarcinoma.[@b5-ott-5-255] Specific novel therapeutic strategies are urgently needed for intrahepatic cholangiocarcinoma.

Epithelial-mesenchymal transition (EMT) is essential for phenotypic transition during embryogenesis and wound healing, and could also be reactivated during the malignant progression of numerous cancers.[@b6-ott-5-255] The process of EMT is characterized by loss of the epithelial marker, E-cadherin, abnormal nuclear location of β-catenin, and loss of acquired mesenchymal markers, such as vimentin and N-cadherin. *Snail*, *sphingosine-1-phosphate*, and *Twist* are considered to be master genes triggering EMT by strong repression of E-cadherin.[@b7-ott-5-255] Expression of EMT biomarkers has been investigated in various cancers, including those of gastric origin.[@b8-ott-5-255] However, the clinicopathological and prognostic significance of multiple EMT-related proteins in cholangiocarcinoma has not as yet been confirmed.

In this study, we investigated the expression of EMT markers in human intrahepatic cholangiocarcinoma, and their relationship with clinical features and prognosis was also determined.

Materials and methods
=====================

Patients
--------

The study subjects included 96 patients with intrahepatic cholangiocarcinoma, who were surgically treated at Huzhou Central Hospital, Zhejiang, China, and the First Affiliated Hospital, Bengbu Medical College, Anhui, China, from 2002 to 2008. All tumors were confirmed pathologically. No patients underwent chemotherapy or radiotherapy before surgery. Postoperative adjuvant treatments were undertaken in a subset of patients with recurrence as follows: 12 cases received 5-fluorouracil-based chemotherapy; seven cases received radiotherapy, and five received both treatment modalities. Cases combined with extrahepatic cholangiocarcinoma were excluded. TNM (tumor-node-metastasis) stages were based on pathological classification. Follow-up information was collected, including patient outcome and time interval between the date of surgical resection and cancer-related death. Patients lost to follow-up and those who died from causes other than cancer were considered as censored data. The median follow-up period was 23 (range 9--61) months. The study was approved by the institutional review board of our institutions, and informed consent was obtained from each patient.

Immunohistochemistry
--------------------

Expression of EMT marker proteins, ie, E-cadherin, N-cadherin, and vimentin and alpha-smooth muscle actin (α-SMA) was detected by immunohistochemistry. Briefly, 4 μm thick sections were deparaffinized, rehydrated, and washed with phosphate-buffered saline. They were then treated with 3% hydrogen peroxide for 20 minutes at room temperature to inactivate endogenous peroxidases, followed by microwave antigen retrieval in 10 mM citric acid (pH 6.0) for 10 minutes. The slides were blocked with 3% bovine serum albumin in phosphate-buffered saline for 30 minutes and incubated with the mouse monoclonal anti-human E-cadherin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, Clone G-10, \#sc-8426, at 1:100 dilution), mouse monoclonal antihuman vimentin antibody (Santa Cruz Biotechnology, Clone V9, \#sc-6260, at 1:100 dilution), mouse monoclonal antihuman vimentin antibody (Santa Cruz Biotechnology, Clone D-4, \#sc-8424, at 1:100 dilution), and mouse monoclonal antihuman α-SMA antibody (Wuhan Boster Biological Technology, Fremont, CA, \# BM0002, at 1:100 dilution) overnight at 4°C. Immunostaining was carried out using the Envision kit (DAKO, Carpinteria, CA) according to the manufacturer's instructions. Immunoreactivity was visualized with diaminobenzidine substrate and was then counterstained with hematoxylin. To create a positive tumor control marker, slides were incubated with rabbit anticytokeratin (DAKO) at 1:100. Mouse IgG at the same concentration instead of the primary antibodies was used as negative controls. Immunohistochemistry staining was evaluated according to a previous study of EMT markers.[@b8-ott-5-255] The sample was recorded in 200× fields, five different fields, and at least 1000 tumor cells were recorded in each sample. Cases were regarded as positive for each antibody when immunoreactivity was present in more than 10% of the cancer cells.

Statistical analysis
--------------------

The Chi-square test was used to evaluate the statistical significance of the relationship between clinicopathological variables and expression of individual EMT-related proteins. The nonparametric Spearman rank correlation coefficient was applied to analyze for correlations between the expression of E-cadherin, vimentin, N-cadherin. The Kaplan-Meier method was used for univariate analysis of EMT markers to predict overall patient survival. A multivariate analysis of clinicopathological variables and EMT markers was performed using the Cox proportional hazard regression model. All statistical analyses were performed with SPSS version 16.0 software (SPSS Inc, Chicago, IL). Statistical significance was set at *P* \< 0.05.

Results
=======

The clinical and pathological characteristics of the patients are shown in [Table 1](#t1-ott-5-255){ref-type="table"}. Immunohistochemical staining was performed to analyze the protein expression of the epithelial protein marker, E-cadherin, and the mesenchymal markers, vimentin and N-cadherin, in tumor specimens. Representative immunohistochemical results are shown in [Figure 1](#f1-ott-5-255){ref-type="fig"}. Epithelial E-cadherin protein loss frequency was observed in 43.8% (42/96) of tumors, and acquired mesenchymal vimentin and N-cadherin protein overexpression frequency was seen in 37.5% (36/96) and 57.3% (55/96) of tumors, respectively.

The relationships between altered EMT protein expression and clinicopathological parameters are summarized in [Table 1](#t1-ott-5-255){ref-type="table"}. Loss of E-cadherin and acquisition of vimentin were found to be significantly related to lymph node metastasis, advanced pTNM stage, and poorly differentiated type. In addition, N-cadherin-positive intrahepatic cholangiocarcinomas had a higher recurrence rate of vascular invasion (41.8%, 23/55) than N-cadherin negative tumors (22.0%, *P* = 0.041).

The Spearman rank correlation test showed that the three EMT-related proteins were closely related to each other in intrahepatic cholangiocarcinoma. Loss of E-cadherin was negatively correlated with vimentin (r = −0.705, *P* = 0.001) and N-cadherin (r = −0.422, *P* = 0.001) expression. Membranous N-cadherin expression also had a statistically significant correlation with increased vimentin expression (r = 0.277, *P* = 0.006). No significant relationship between stromal α-SMA expression and EMT markers was observed in the intrahepatic cholangiocarcinoma tumors.

Overall survival was determined using the log-rank test with respect to expression of the three EMT markers ([Figure 2](#f2-ott-5-255){ref-type="fig"}). In terms of the epithelial marker, E-cadherin, loss was found to be significantly associated with a poor outcome. This was also true for upregulation of the mesenchymal proteins, vimentin and N-cadherin. The three EMT markers and four other statistically significant prognostic factors (lymph node metastasis, venous invasion, pTNM stage, and histology) identified in univariate analysis were entered in the multivariate analysis. Among these factors, loss of E-cadherin expression and lymph node metastasis were shown to be independent prognostic indicators in patients with intrahepatic cholangiocarcinoma. However, vimentin and N-cadherin expression had no prognostic significance in multivariate analysis ([Table 2](#t2-ott-5-255){ref-type="table"}).

Among the positive cases, 39 tumors demonstrated coexistence of two EMT markers and 27 cases showed coexistence of three EMT markers. As seen in [Table 1](#t1-ott-5-255){ref-type="table"} and [Figure 2](#f2-ott-5-255){ref-type="fig"}, there was a trend towards coexistence of multiple EMT markers associated with lymph node metastasis, pTNM stage, histology, and shorter overall survival. Furthermore, there was also a significant association between coexistence of two EMT markers and vascular invasion.

Discussion
==========

During progression of cancer, induction of EMT has been associated with acquisition of stemness properties, metastasis, and resistance to chemotherapy.[@b9-ott-5-255] The clinical and prognostic significance of EMT has been reported in various human cancers.

Although immunostaining of individual EMT markers, such as E-cadherin and β-catenin, has been reported in several previous studies involving small sample sizes,[@b10-ott-5-255],[@b11-ott-5-255] the expression profile of multiple EMT markers in intrahepatic cholangiocarcinoma has not been clarified.

Circumstantial evidence supports EMT being closely associated with progression of intrahepatic cholangiocarcinoma. Seol et al[@b12-ott-5-255] analyzed the gene profiling of nine cancer cell lines generated from intrahepatic cholangiocarcinomas, and found upregulation of the EMT-related proteins, vimentin and Twist1. Dos Santos et al[@b13-ott-5-255] examined the proteomic profiling of microdissected intrahepatic cholangiocarcinoma cells, and found that the protein alterations in these cells were very similar to those reported in the A549 human lung adenocarcinoma cell line during EMT induced by transforming growth factor beta, which has been demonstrated to be increased in intrahepatic cholangiocarcinoma.[@b14-ott-5-255],[@b15-ott-5-255] It has also been reported that reduced expression of beta-catenin is detected in a majority of biliary tumors, and their downregulation correlates with high-grade malignancy.[@b16-ott-5-255]

In this study, we evaluated immunohistochemically the expression of three established EMT biomarkers which have been most frequently investigated in 96 consecutive intrahepatic cholangiocarcinoma specimens, and found that downregulation of E-cadherin and upregulation of vimentin and N-cadherin was associated with aggressive biological behavior, including poor differentiation, advanced stage, positive lymph node involvement, and venous infiltration. Our findings are consistent with the findings of previous researchers.[@b10-ott-5-255],[@b11-ott-5-255]

We extended the previous studies to confirm that expression of three EMT proteins was closely related in intrahepatic cholangiocarcinoma. Kaplan-Meier univariate analysis also showed that aberrant expression of the individual EMT-related proteins showed a trend toward poorer outcomes. Furthermore, loss of E-cadherin had an independent prognostic value in predicting outcomes in patients with primary intrahepatic cholangiocarcinoma. Taken together, our findings suggest that the EMT process may be an important molecular event during progression and metastasis of intrahepatic cholangiocarcinoma, which is in concordance with several published in vitro studies. Interaction of carcinoma and stromal cells plays an important role in the regulation of EMT in carcinomas. Schulte et al[@b17-ott-5-255] revealed significant correlations between stromal myofibroblasts and the EMT markers, Snail and Slug. However, in this study, using α-SMA as a marker for stromal myofibroblasts, no statistically significant relationship was observed between stromal myofibroblasts and EMT markers in intrahepatic cholangiocarcinoma.

Given the aggressive nature and lack of effective adjuvant treatment modalities for intrahepatic cholangiocarcinoma, complete surgical resection is still the only therapeutic option for patients with the disease. However, even patients undergoing radical surgical resection are still at high risk for recurrence, and postoperative survival remains unsatisfactory. Considering that the EMT phenotype is closely related to aggressive behavior and a poor prognosis in intrahepatic cholangiocarcinoma, we suggest that EMT might not only provide a new classification scheme, but might also offer a promising therapeutic target for patients with the disease. A couple of studies have proposed strategies to inhibit EMT. Li et al[@b18-ott-5-255] suggested that application of miR-214 might inhibit EMT by directly targeting the *Twist* gene in intrahepatic cholangiocarcinoma. Araki et al[@b19-ott-5-255] also indicated that transforming growth factor beta could be regarded as a candidate target to reverse EMT in biliary tumors.

Conclusion
==========

In the present study, we have found that expression of EMT-related proteins is closely associated with tumor progression and a poor prognosis in intrahepatic cholangiocarcinoma, suggesting that the EMT process may act as an important molecular event during the progression and metastasis of intrahepatic cholangiocarcinoma. We propose that EMT markers would have clinical implications for clinical classification; furthermore, inhibition of EMT might offer a novel promising target for the treatment of patients with intrahepatic cholangiocarcinoma.
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![Representative immunohistochemical images of three epithelial-mesenchymal transition markers in intrahepatic cholangiocarcinoma. (**A**) E-cadherin was strongly expressed in the plasma membrane of the tumor cells; (**B**) demonstration of loss of membranous E-cadherin in tumor cells; (**C**) negative N-cadherin expression with a positivity less than 10%; (**D**) demonstration of N-cadherin in the membrane and cytoplasm of tumor cells; (**E**) negative expression of vimentin in cancer cells while stromal cells were positively stained; and (**F**) acquired vimentin expression in cancer cells.](ott-5-255f1){#f1-ott-5-255}

###### 

Survival analysis of three epithelial-mesenchymal transition markers in univariate analysis using the Kaplan-Meier method determined by the log-rank test. E-cadherin loss (**A**) and upregulation of mesenchymal proteins vimentin (**B**) and N-cadherin (**C**) were found to be significantly associated with a poor outcome. There was also a trend toward coexistence of multiple epithelial-mesenchymal transition markers (**D** and **E**) associated with much more shorter overall survival.
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###### 

Correlations between epithelial-mesenchymal transition markers and clinicopathological characteristics

                          E-cadherin   Vimentin   N-cadherin   With two EMT markers   With three EMT markers                                                         
  ----------------------- ------------ ---------- ------------ ---------------------- ------------------------ ------- ---- ---- ------- ---- ---- ------- ---- ---- -------
  Age (years)                                                                                                                                                        
   \<65                   25           28         0.453        29                     24                       0.080   22   31   0.792   30   23   0.539   35   18   0.158
   ≥65                    17           26                      31                     12                               19   24           27   16           34   9    
  Gender                                                                                                                                                             
   Female                 13           17         0.956        19                     11                       0.909   13   17   0.933   17   13   0.716   20   10   0.444
   Male                   29           37                      41                     25                               28   38           40   26           49   17   
  Tumor size                                                                                                                                                         
   \<5 cm                 31           43         0.501        48                     26                       0.380   29   45   0.201   46   28   0.308   53   21   0.919
   ≥5 cm                  11           11                      12                     10                               12   10           11   11           16   6    
  Lymph node metastasis                                                                                                                                              
   Negative               20           42         0.002        46                     16                       0.001   28   34   0.512   43   19   0.007   50   12   0.010
   Positive               22           12                      14                     20                               13   21           14   20           19   15   
  Vascular invasion                                                                                                                                                  
   Negative               24           40         0.081        44                     20                       0.074   32   32   0.041   43   21   0.028   48   16   0.336
   Positive               18           14                      16                     16                               9    23           14   18           21   11   
  Neural invasion                                                                                                                                                    
   Negative               24           37         0.251        42                     19                       0.090   26   35   0.982   40   21   0.103   46   15   0.309
   Positive               18           17                      18                     17                               15   20           17   18           23   12   
  pTNM stage                                                                                                                                                         
   I and II               14           34         0.040        37                     11                       0.030   19   29   0.536   35   13   0.007   39   9    0.041
   III and IV             28           20                      23                     25                               22   26           22   26           30   18   
  Histology                                                                                                                                                          
   Differentiated         16           35         0.009        40                     11                       0.001   23   28   0.614   37   14   0.005   44   7    0.001
   Undifferentiated       26           19                      20                     25                               18   27           20   25           25   20   

**Abbreviation:** TNM, tumor-node-metastasis.

###### 

Multivariate analysis of predictive factors for overall survival

  Variables                                 OS                     
  ----------------------------------------- ------- -------------- -------
  LN metastasis                                                    
   Positive versus negative                 2.416   1.166--5.003   0.018
  Vascular invasion                                                
   Positive versus negative                 1.222   0.703--2.124   0.478
  pTNM stage                                                       
   I and II versus III and IV               1.192   0.613--2.319   0.604
  Histology                                                        
   Differentiated versus undifferentiated   0.954   0.535--1.701   0.873
  E-cadherin                                                       
   Present versus absent                    0.157   0.061--0.402   0.001
  Vimentin                                                         
   Present versus absent                    0.678   0.304--1.515   0.344
  N-cadherin                                                       
   Present versus absent                    1.320   0.732--2.379   0.356

**Abbreviations:** HR, hazards ratio; LN, lymph node; TNM, tumor-node-metastasis; OS, overall survival; CI, confidence interval.
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